Metachromatic leukodystrophy – Diagnostics – Overview of Information and Clinical Research

Diagnosing metachromatic leukodystrophy requires a combination of specialized tests that look at enzyme activity, genetic changes, and how the disease affects the brain and nervous system. Early and accurate diagnosis is crucial because it can open the door to treatment options that may slow the disease’s progression, especially when caught before symptoms fully develop.

Who Should Undergo Diagnostics and When

Understanding when to seek diagnostic testing for metachromatic leukodystrophy can make a significant difference in managing this rare genetic condition. Metachromatic leukodystrophy, often shortened to MLD, is a hereditary disorder that affects the white matter of the brain and spinal cord, leading to a progressive decline in mental and physical abilities.^[1]

Diagnostic testing becomes especially important when certain warning signs appear. For babies and young children, parents or caregivers might notice difficulty walking after the first year of life, usually between 15 and 24 months. Other concerning signs include developmental delays, weak muscle tone, trouble speaking, or problems with swallowing. These symptoms often point to what doctors call the late infantile form of MLD, which is the most common type, representing about 50 to 60 percent of all cases.^[2]

In older children, between ages 3 and 10, the disease can present differently. Rather than primarily physical symptoms, parents and teachers might first notice changes in school performance, intellectual decline, or behavioral difficulties. Personality changes, problems controlling muscle movements, or seizures may also emerge. This is known as the juvenile form of MLD, accounting for roughly 20 to 30 percent of cases.^[2]

Adults can also develop MLD, typically after age 16 and sometimes not until their 40s or 50s. In these cases, the first signs are often psychiatric in nature. Behavioral problems, difficulties at school or work, substance use disorders, or psychiatric symptoms such as delusions or hallucinations might be the initial clues. Adult-onset MLD represents about 15 to 20 percent of all cases and tends to progress more slowly than the forms that appear in childhood.^[4]

⚠️ Important

If an older sibling has been diagnosed with MLD, it is essential to test younger siblings before symptoms appear. Early diagnosis in a pre-symptomatic child can allow for treatment interventions that may significantly improve outcomes and quality of life.^[14]

Because MLD is inherited in what’s called an autosomal recessive pattern, both parents must carry a copy of the affected gene for their child to develop the disorder. This means that if one child in a family is diagnosed, there is a risk that other siblings could also have the condition. Testing younger siblings who have not yet shown symptoms is strongly recommended, as early intervention can be life-changing.^[5]

People who have a family history of MLD should also consider diagnostic testing, particularly if they are planning to have children. Genetic counseling is recommended for families with a known history of the disorder, as it can help them understand their risks and make informed decisions about testing and family planning.^[5]

Classic Diagnostic Methods

Diagnosing metachromatic leukodystrophy involves several steps and different types of tests. Doctors typically start with a physical examination that includes a detailed neurological exam. They will review the patient’s symptoms and medical history to look for signs consistent with MLD.^[9]

One of the most important diagnostic tools is a blood test that measures the activity of an enzyme called arylsulfatase A, often abbreviated as ARSA. In people with MLD, this enzyme is either missing or present in very low amounts. The enzyme’s job is to break down fatty substances called sulfatides. When the enzyme doesn’t work properly, sulfatides build up in the cells, particularly in the brain and nervous system, causing progressive damage.^[2]

A blood test can show a deficiency of arylsulfatase A, which strongly suggests MLD. However, some people who are simply carriers of the gene also have low enzyme levels, so additional testing is often needed to confirm the diagnosis.^[8]

Urine tests can also be helpful. These tests check for elevated levels of sulfatides in the urine. Because sulfatides accumulate in the body when the enzyme is deficient, finding high amounts in urine is another sign of MLD.^[5]

Genetic testing is another critical component of diagnosis. Doctors can conduct tests to look for mutations, or changes, in the ARSA gene located on chromosome 22. In almost all cases of MLD, mutations in this gene are responsible for the disease. In rare cases, the disorder can be caused by mutations in a different gene called PSAP, which produces a protein called saposin B that also helps break down sulfatides. Genetic testing can identify these mutations and confirm the diagnosis.^[3]

Prenatal testing is available for pregnant women who are known carriers or have a family history of MLD. This testing can determine whether the unborn child has inherited the genetic mutations that cause the disease.^[5]

Brain imaging is another valuable diagnostic tool. A magnetic resonance imaging (MRI) scan uses powerful magnets and radio waves to create detailed pictures of the brain. In people with MLD, the MRI can reveal a characteristic striped pattern, sometimes called a “tigroid” pattern, in the white matter of the brain. This pattern is caused by the accumulation of sulfatides and the resulting damage to myelin, the protective coating around nerve fibers.^[9]

A nerve conduction study is another test that may be performed. This test measures how well electrical signals travel through the nerves by placing small electrodes on the skin. Because MLD often causes nerve damage, particularly in the peripheral nerves (the nerves outside the brain and spinal cord), this test can detect problems with nerve function. People with MLD commonly develop peripheral neuropathy, which is a loss of sensation in the extremities.^[9]

In some cases, doctors may perform a nerve biopsy, where a small sample of nerve tissue is removed and examined under a microscope. This can show the buildup of sulfatides within nerve cells.^[8]

Psychological and cognitive tests may also be part of the diagnostic process, particularly for juvenile and adult forms of MLD. These tests assess thinking abilities, memory, behavior, and emotional function. Because psychiatric and behavioral problems are often the first signs of the disease in older patients, these assessments can help determine how MLD is affecting brain function.^[9]

Diagnostics for Clinical Trial Qualification

For families exploring treatment options through clinical trials, understanding the specific diagnostic criteria used to qualify patients is essential. Clinical trials for MLD often have strict eligibility requirements based on the form of the disease, the patient’s age, symptom status, and results of specific tests.^[12]

Most clinical trials require confirmation of MLD through enzyme testing and genetic analysis. A blood test showing deficient arylsulfatase A enzyme activity is typically required, along with genetic testing that identifies mutations in the ARSA or PSAP genes. These tests confirm that the patient truly has MLD and not a different condition with similar symptoms.^[3]

The patient’s symptom status is another crucial factor. Many trials, particularly those involving gene therapy, are designed for pre-symptomatic or early-symptomatic patients. This means that children who have been diagnosed with MLD but have not yet developed significant symptoms, or who are only mildly symptomatic, are often the best candidates. The reason is that these treatments aim to prevent or slow the progression of the disease before extensive damage occurs.^[13]

For example, gene therapy trials have typically recruited pre-symptomatic children with a confirmed diagnosis of late infantile or early juvenile MLD. These trials often exclude children who have already undergone other treatments, such as stem cell transplantation, and those whose disease has progressed beyond a certain point.^[14]

Brain imaging, particularly MRI scans, is also used to assess disease severity and progression. Clinical trials may require baseline MRI scans to document the extent of white matter damage before treatment begins. Follow-up scans are then used to measure whether the treatment is slowing or preventing further deterioration.^[9]

Neurological assessments and developmental testing are often part of the screening process for clinical trials. These evaluations establish the patient’s current level of motor function, cognitive abilities, and overall neurological health. They provide a baseline that researchers can use to measure the effectiveness of the experimental treatment over time.^[9]

Some clinical trials also require patients to undergo tests to evaluate the function of major organ systems, including the heart, lungs, liver, and kidneys. This is particularly important for treatments like hematopoietic stem cell transplantation, which involves replacing the patient’s defective cells with healthy cells from a donor. The conditioning regimen for transplantation can be physically demanding, so ensuring that the patient’s organs are functioning well is crucial.^[10]

⚠️ Important

If you are considering enrolling in a clinical trial for MLD, it is essential to work closely with a multidisciplinary medical team. This team may include specialists in genetics, metabolism, neurology, and transplantation, who can help determine whether a trial is appropriate and guide you through the screening process.^[10]

For trials involving enzyme replacement therapy delivered directly into the spinal fluid (intrathecal administration), additional tests may be required to ensure safe delivery of the treatment. These can include assessments of spinal anatomy and cerebrospinal fluid flow.^[13]

Age is another critical factor in clinical trial eligibility. Some trials are designed specifically for late infantile MLD and may only accept children under a certain age, such as younger than 7 years. Other trials may focus on juvenile or adult forms of the disease. Understanding the specific age requirements is important when exploring trial options.^[13]

Finally, clinical trials may exclude patients who have received certain prior treatments. For instance, a trial testing a new therapy might not accept patients who have already had a bone marrow transplant or gene therapy, as these prior interventions could affect the results of the experimental treatment.^[14]

Prognosis and Survival Rate

Prognosis

The prognosis for metachromatic leukodystrophy varies depending on the form of the disease and the age at which symptoms first appear. Unfortunately, MLD is a progressive disease, meaning that symptoms worsen over time. The outlook is generally more serious for patients with earlier onset of the disease.^[2]

Children with late infantile MLD, the most common and rapidly progressing form, typically face the most challenging prognosis. After symptoms begin, usually between 12 and 20 months of age, the disease progresses quickly. Affected children experience walking difficulties that eventually lead to an inability to walk, developmental delays, loss of speech, blindness, difficulty swallowing, and dementia. Without treatment, most children with late infantile MLD do not survive past age 5, often dying much sooner.^[2]

Juvenile MLD, which begins between ages 3 and 10, progresses more slowly than the late infantile form. The first symptoms often include declining school performance, behavioral difficulties, and personality changes, followed by motor problems, peripheral neuropathy, seizures, and dementia. The prognosis for juvenile MLD is variable, but death typically occurs within 10 to 20 years after the onset of symptoms. Some patients may live for several decades after symptoms begin, particularly if the disease starts later in the juvenile period.^[2]

Adult-onset MLD, which typically begins after age 16 and sometimes not until the 40s or 50s, has the slowest progression. The first symptoms are often psychiatric changes, including behavioral problems, mood disturbances, or difficulties at work or school. Motor symptoms may be mild or absent initially. Patients with adult-onset MLD typically survive for about 6 to 14 years after diagnosis, though the disease course can be more protracted, lasting a decade or more. In general, the older the age at diagnosis, the slower the disease progresses.^[2]

For patients who receive early intervention, particularly those who are pre-symptomatic or only mildly symptomatic at the time of treatment, the prognosis may be significantly better. Treatments such as hematopoietic stem cell transplantation can stabilize neurocognitive function in pre-symptomatic and early-symptomatic patients with juvenile and adult MLD, providing a clinical and survival benefit. However, even with treatment, motor symptoms may continue to progress.^[13]

Gene therapy has shown promising results for pre-symptomatic and early-symptomatic patients with late infantile MLD, with clinical trials demonstrating improved functional outcomes. Nevertheless, long-term treatment effects and safety outcomes beyond 15 years are still being studied.^[13]

Survival rate

Survival rates for metachromatic leukodystrophy depend heavily on the form of the disease and when treatment is initiated. The disease course typically runs anywhere from 3 to 20 years or more from the onset of symptoms.^[21]

In late infantile MLD, without treatment, survival is typically limited to early childhood, with most children dying by age 5. The rapid progression of this form means that affected children often lose all motor and cognitive function within a few years of symptom onset.^[2]

Juvenile MLD has a more variable survival rate. Children diagnosed with this form can live for 10 to 20 years after symptoms appear, though the quality of life declines progressively over time. Some patients, particularly those with late-juvenile onset, may survive longer, especially if they receive supportive care and medical interventions to manage symptoms.^[2]

Adults with MLD can survive for 6 to 14 years after diagnosis, and in some cases, up to 20 to 30 years, particularly if the disease onset is later in life. The slower progression of adult-onset MLD means that patients may have periods of relative stability interspersed with periods of more rapid decline.^[4]

It is important to note that these survival estimates apply to untreated or symptomatically treated patients. Early detection and intervention, particularly with stem cell transplantation or gene therapy in pre-symptomatic or early-symptomatic patients, can significantly alter these outcomes. In some cases, patients who receive early treatment have shown little to no degeneration after 25 years.^[14]

People with MLD are expected to have a shorter-than-normal lifespan. The earlier the age at diagnosis, the more quickly the disease progresses and the shorter the survival time. However, advances in treatment and supportive care are improving outcomes for some patients, offering hope for better quality of life and longer survival.^[21]

#1 Clinical Trials Search in Europe